An FDA advisory panel has voted 5-0 in favor of recommending approval of Cambridge, MA-based Genzyme’s (NASDAQ:[[ticker:GENZ]]) osteoarthritis treatment hylan GF 20 (Synvisc-One) in single injections, the company announced Tuesday. Christopher Raymond, an analyst for Robert W. Baird, reiterated his “outperform” rating on Genzyme’s stock with the following note: “Although FDA does not necessarily have to follow the recommendation of the panel, we think Synvisc-One’s approval by its December 23 action date is now more likely considering the panel’s discussion indicating Synvisc-One is effective for the treatment of osteoarthritis.”
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
